Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

Contributed by: Business Wire

Logo

Tags

Biotechnology

Pharmaceutical

Other Manufacturing

Oncology

Health

Supply Chain Management

Manufacturing

Retail

Forma Life Sciences CAVHANZA

More Like This

Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

Nanoform's biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned

Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide

Nanoform and PlusVitech partner to repurpose aprepitant as a treatment for lung cancer

Dr. Aron Blaesi, inventor of expandable, gastroretentive fibrous dosage forms presenting dosage forms before and after expansion due to water absorption. (Photo: Business Wire)

Enzian Pharmaceutics Develops a Novel Dosage Form for Enhanced Efficacy and Reduced Side Effects of Cancer Therapies

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis